Christopher P Conlon
Overview
Explore the profile of Christopher P Conlon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moore S, Kronsteiner B, Longet S, Adele S, Deeks A, Liu C, et al.
Med
. 2023 Mar;
4(3):191-215.e9.
PMID: 36863347
Background: Both infection and vaccination, alone or in combination, generate antibody and T cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the maintenance of such responses-and hence...
2.
Johnson S, Phillips E, Adele S, Longet S, Malone T, Mason C, et al.
Clin Exp Immunol
. 2023 Feb;
212(3):249-261.
PMID: 36807499
T cells are important in preventing severe disease from SARS-CoV-2, but scalable and field-adaptable alternatives to expert T-cell assays are needed. The interferon-gamma release assay QuantiFERON platform was developed to...
3.
Phillips E, Adele S, Malone T, Deeks A, Stafford L, Dobson S, et al.
Clin Exp Immunol
. 2022 May;
209(1):90-98.
PMID: 35522978
T-cell responses to SARS-CoV-2 following infection and vaccination are less characterized than antibody responses, due to a more complex experimental pathway. We measured T-cell responses in 108 healthcare workers (HCWs)...
4.
Angyal A, Longet S, Moore S, Payne R, Harding A, Tipton T, et al.
Lancet Microbe
. 2021 Nov;
3(1):e21-e31.
PMID: 34778853
Background: Previous infection with SARS-CoV-2 affects the immune response to the first dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and antibody responses in health-care workers with...
5.
Payne R, Longet S, Austin J, Skelly D, Dejnirattisai W, Adele S, et al.
Cell
. 2021 Nov;
184(23):5699-5714.e11.
PMID: 34735795
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial...
6.
Skelly D, Harding A, Gilbert-Jaramillo J, Knight M, Longet S, Brown A, et al.
Nat Commun
. 2021 Aug;
12(1):5061.
PMID: 34404775
The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing...
7.
Lumley S, Rodger G, Constantinides B, Sanderson N, Chau K, Street T, et al.
Clin Infect Dis
. 2021 Jul;
74(7):1208-1219.
PMID: 34216472
Background: Natural and vaccine-induced immunity will play a key role in controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. SARS-CoV-2 variants have the potential to evade natural and...
8.
Riste M, Marshall J, Satti I, Harris S, Wilkie M, Ramon R, et al.
Vaccines (Basel)
. 2021 Apr;
9(4).
PMID: 33923628
The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but...
9.
Townsend A, Rijal P, Xiao J, Tan T, Huang K, Schimanski L, et al.
Nat Commun
. 2021 Mar;
12(1):1951.
PMID: 33782398
Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of seroconversion in populations, and for seeking evidence for a level of antibody that may be protective against COVID-19...
10.
Eyre D, Lumley S, ODonnell D, Stoesser N, Matthews P, Howarth A, et al.
BMC Infect Dis
. 2021 Feb;
21(1):187.
PMID: 33602152
Background: Thresholds for SARS-CoV-2 antibody assays have typically been determined using samples from symptomatic, often hospitalised, patients. In this setting the sensitivity and specificity of the best performing assays can...